Medical News

RSS

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.

14 Feb 2011

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

SpineSmith, a Texas-based medical device company, today announces the company will begin the national rollout in March of the VisuALIF, following a successful Alpha launch.

14 Feb 2011

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced completion of its global Phase III ORACAL trial testing the company's once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. Results from the ORACAL trial are expected in early spring. In addition, Tarsa announced initiation of a new Phase II study of its oral calcitonin for the prevention of postmenopausal osteoporosis.

14 Feb 2011

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in patients with relapsed ovarian cancer.

14 Feb 2011

NHGRI's new strategic plan to identify genetic bases of most single-gene disorders

A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).

14 Feb 2011

CD&R affiliate to acquire EMSC

Emergency Medical Services Corporation and Clayton, Dubilier & Rice, LLC (CD&R) announced today a definitive merger agreement under which an affiliate of CD&R formed to complete the merger will acquire EMSC. Under the terms of the agreement EMSC stockholders would receive, at the closing of the transaction, $64.00 in cash for each share of EMSC Class A common stock and Class B common stock and each LP Exchangeable Unit.

14 Feb 2011

First Edition: February 14, 2011

Today's headlines are focused on President Obama's budget proposal and what it does and does not include.

14 Feb 2011

Public-sector research has had an immediate effect on improving public health: Study

AUTM President Ashley Stevens, D. Phil. (Oxon), CLP is the lead author of The Role of Public Sector Research in the Discovery of Drugs and Vaccines, a paper published in the Feb. 10 issue of The New England Journal of Medicine.

14 Feb 2011

Johns Hopkins nursing students promote healthy diet and lifestyles in Baltimore's vulnerable communities

When Johns Hopkins nursing students aren't hitting the books or practicing clinical skills, they're promoting healthy diet and lifestyles in Baltimore's vulnerable communities. These students are cooking up some fun with local residents with support from Johns Hopkins University Alumni Association grants.

14 Feb 2011

First smartphone to natively communicate with ULP ANT+ network of health and fitness devices

ANT Wireless, a division of Dynastream Innovations Inc., and Texas Instruments Incorporated today showcase the Sony Ericsson Xperia™ arc, the first commercially available smartphone to natively communicate with the ultra-low power (ULP) ANT+ network of health and fitness devices.

14 Feb 2011

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

AngioDynamics announced today the launch of a new Morpheus® SMART PICC bedside insertion kit and new 5 French Dual Lumen Peripherally Inserted Central Catheter (PICC) as part of the continued growth of its Morpheus SMART PICC line.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

Napo Pharmaceuticals, Inc. is pleased to announce the positive results of a successfully completed Phase 2 study of crofelemer for the treatment of hospitalized adult patients with mild to moderate acute watery diarrhea conducted by its partner Glenmark Pharmaceuticals Ltd..

14 Feb 2011

First chromogenic culture medium to simultaneously detect Salmonella and Shigella

Hardy Diagnostics, an ISO certified biomedical firm, is pleased to announce the release of HardyCHROM™ SS, a highly selective chromogenic medium recommended for use as a primary screening medium for the isolation and differentiation of Salmonella and Shigella spp. from stool cultures. These two pathogens can be easily distinguished from non-pathogenic enteric bacteria based on colony color.

14 Feb 2011

Numira acquires Ricerca' Efficacy Pharmacology operating unit

Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, announced today that it has acquired the Efficacy Pharmacology operating unit of Ricerca Biosciences, LLC., located in Bothell, WA.

14 Feb 2011

ArthroCare fourth quarter total revenue increases to $92.6 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the fourth quarter and year ended December 31, 2010.

14 Feb 2011

Vitamin D levels not linked to prostate cancer development

Vitamin D levels do not affect men's chances of developing prostate cancer, according to new research published in the journal Cancer Causes and Control.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

FDA accepts King's ACUROX NDA for filing with Priority review classification

Acura Pharmaceuticals, Inc. today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King's New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) with a Priority review classification and a Prescription Drug User Fee Act (PDUFA) date of June 17, 2011.

14 Feb 2011

Elite third quarter consolidated revenues increase 34% to $1.2 million

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release product formulations, announced results for the fiscal third quarter ended December 31, 2011.

14 Feb 2011

Medical News

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

Tarsa completes oral calcitonin Phase III trial for treatment of postmenopausal osteoporosis

OXiGENE, NCI/CTEP and GOG collaborate on ZYBRESTAT Phase 2 study in relapsed ovarian cancer

NHGRI's new strategic plan to identify genetic bases of most single-gene disorders

CD&R affiliate to acquire EMSC

First Edition: February 14, 2011

Public-sector research has had an immediate effect on improving public health: Study

Johns Hopkins nursing students promote healthy diet and lifestyles in Baltimore's vulnerable communities

First smartphone to natively communicate with ULP ANT+ network of health and fitness devices

AngioDynamics launches new Morpheus SMART PICC bedside insertion kit and 5 French Dual Lumen PICC

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Positive results from Glenmark's crofelemer Phase 2 study in acute watery diarrhea

First chromogenic culture medium to simultaneously detect Salmonella and Shigella

Numira acquires Ricerca' Efficacy Pharmacology operating unit

ArthroCare fourth quarter total revenue increases to $92.6 million

Vitamin D levels not linked to prostate cancer development

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

FDA accepts King's ACUROX NDA for filing with Priority review classification

Elite third quarter consolidated revenues increase 34% to $1.2 million

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News